Posts by Craig S. Hilliard

Bard Agrees to Settle 500 Pelvic Mesh Cases

Posted in Medical Devices, Stark Events, Transvaginal Mesh

The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were… Continue Reading

Endo International Settles Pelvic Mesh Cases for $830 Million

Posted in Transvaginal Mesh

Endo International Plc (“Endo”) has agreed to pay $830 million to resolve legal claims from women who allege that they were injured by the company’s transvaginal mesh devices. Endo said the settlement will cover a “substantial majority” of the mesh litigation brought against its American Medical Systems subsidiary.  This settlement comes only one year after… Continue Reading

FDA Announces New Safety Assessment for Pradaxa

Posted in Pradaxa

The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use. Physicians and analysts have commented that the health risks associated with… Continue Reading

Parties Preparing Consolidated Pleadings in Byetta, Januvia/Janumet and Victoza Litigation

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was centralized… Continue Reading

Johnson & Johnson Reportedly Agrees to Settle DePuy ASR Lawsuits for $4 Billion

Posted in DePuy ASR, DePuy Pinnacle

As we have previously reported, DePuy Orthopaedics, Inc. has recalled its ASR hip replacement device. There are thousands of cases pending across the country related to the ASR device. These cases continue to proceed in state and federal courts. The New York Times reports that DePuy Orthopaedics, Inc., a subsidiary of Johnson & Johnson, has… Continue Reading

ADA Asks for Incretin Mimetic Data

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, recent evidence suggests that incretin mimetic medications are linked to pancreatitis and pancreatic cancer. The American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications to make patient level data on their products available for an independent review. The ADA is concerned… Continue Reading

Motion to Consolidate Incretin Mimetic Cases into One Multidistrict Litigation Currently Pending

Posted in Byetta, Januvia/Janumet and Victoza, Defective Drugs

Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer. A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument,… Continue Reading

New Study Suggests Plavix May Increase the Risk of Heart Attack or Stroke

Posted in Defective Drugs, Plavix

Plavix®, marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals, is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets.  The drug works to prevent blood clots.  A recent study by… Continue Reading

The United States Department of Justice is Concerned with Plavix®

Posted in Defective Drugs, Plavix

The United States Department of Justice (“DOJ”) is concerned that the dangers of Plavix® were not properly identified by its manufacturers Sanofi-Aventis and Bristol-Myers Squibb.  The DOJ is concerned that the manufacturers failed to disclose certain information in hopes of misleading consumers about the safety of the drug.  Studies show that certain individuals have a… Continue Reading

New Jersey Jury Awards $3.5 Million in First Vaginal Mesh Trial

Posted in Medical Devices, Transvaginal Mesh

Last month, an Atlantic County jury awarded a former nurse $3.35 million in compensatory damages for injuries she suffered from a vaginal mesh implant made by Johnson & Johnson. Three days following the verdict, the jury also awarded $7.76 million in punitive damages.  The attorney for Johnson & Johnson admitted that her company “didn’t do… Continue Reading

Jury Awards Plaintiff $8.3 Million in First DePuy ASR Trial

Posted in DePuy ASR, Medical Devices

As we previously reported, the first trial of the approximately 10,000 DePuy ASR hip replacement lawsuits commenced in Los Angeles, California in late January 2013. On March 11, 2013, a California jury awarded the plaintiff $8,338,000 in compensatory damages after concluding that the ASR total hip device was defectively designed.  The award consisted of $338,000… Continue Reading

The Number of Pradaxa Injuries Continue to Climb

Posted in Pradaxa

Pradaxa stormed the market in 2010 and was widely prescribed as an anticoagulant drug used to prevent or treat blood clots.  Initially, it seemed effective at reducing the risk of stroke, particularly in patients with atrial fibrillation. The manufacturer, German-based Boehringer Ingelheim Pharmaceuticals, Inc., has realized more than $ 1 billion in sales from the… Continue Reading

Patients Taking Pradaxa at 33% Higher Risk

Posted in Pradaxa

According to recent reports, patients that are taking the anti-clotting drug Pradaxa have a 33% higher risk of heart attack or severe symptoms of heart disease than patients taking Warfarin. The finding, from Cleveland Clinic researchers Ken Uchino, MD, and Adrian V. Hernandez, MD, PhD, is based on data from seven clinical trials that enrolled… Continue Reading

Depositions of DePuy Executives Scheduled

Posted in DePuy ASR, DePuy Pinnacle, Medical Devices

DePuy ASR hip lawsuits in the federal consolidated action, In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (“MDL No. 2197”), continue to proceed with several depositions of DePuy executives scheduled to take place in the next three months. On August 22, 2012, eight depositions were noticed in the federal DePuy ASR hip… Continue Reading

Bayer Yaz and Yasmin Cases May Settle Within a Year

Posted in Defective Drugs, Yaz/Yasmin and Ocella

On July 11, 2012, The Madison Record reported that the special master appointed to oversee settlement negotiations for the federal MDL case, Stephen Saltzburg, estimates that negotiations could be concluded within a year. To date, it is reported that, almost 2,000 lawsuits have settled. As we previously advised, Bayer reports that it has set aside… Continue Reading

Recent Study Links and Yasmin to Yaz Stroke and Heart Attack

Posted in Defective Drugs, Yaz/Yasmin and Ocella

In June 2012, a study, published in the New England Journal of Medicine, reported that that birth control products containing combined estrogen-progestin, such as Yaz or Yasmin, may double a woman’s risk of stroke and heart attack compared to other hormonal contraceptives. The study, based on data compiled over 15 years from more than 1.5… Continue Reading

Democrats Endorse Bill in Congress to Hold Generic Drugmakers Liable

Posted in Darvocet and Darvon, Defective Drugs

Bills were just recently introduced in the US House of Representatives and the US Senate which would effectively overrule the Supreme Court’s decision 2011 decision in Pliva v. Mensing by “allow[ing] generic drug companies to be held liable under state tort law for failing to update warning labels with known dangers.” In a 5-4 split,… Continue Reading

Johnson & Johnson Continued Marketing FDA Rejected Hip Device in Europe

Posted in DePuy ASR, DePuy Pinnacle, Medical Devices

According to a recent New York Times article, Johnson & Johnson continued to market an artificial hip replacement in Europe, despite the Food and Drug Administration (FDA) rejecting its sale in the United States, based on safety concerns.  The company also continued to sell a similarly designed device in the United States, the articular surface… Continue Reading